China Pharma Holdings (CPHI) Common Equity (2010 - 2026)

China Pharma Holdings has reported Common Equity for 17 years, with the latest figure at $37.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 431.21% year-over-year to $37.0 million; the trailing twelve-month figure through Mar 2026 stood at $37.0 million (up 431.21% YoY), and the FY2025 full-year result was $22.7 million, up 193.5% from the prior year.
• Common Equity for Q1 2026 stood at $37.0 million, up from $22.7 million in the prior quarter.
• The five-year high for Common Equity was $37.0 million in Q1 2026, with the low at $2.8 million in Q3 2022.
• Historically, Common Equity has averaged $8.9 million across 5 years, with a median of $6.5 million in 2024.
• Annual changes were most pronounced in 2022 — Common Equity plunged 58.64% — and 2026, when it soared 431.21%.
• China Pharma Holdings' Common Equity stood at $4.3 million in 2022, then soared by 73.77% to $7.5 million in 2023, then increased by 3.93% to $7.7 million in 2024, then soared by 193.5% to $22.7 million in 2025, then jumped by 62.82% to $37.0 million in 2026.
• The last three Common Equity figures came in at $37.0 million (Q1 2026), $22.7 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.